Menu
Scroll to Top
VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. With a first-in-class, non-invasive eyedrop as its lead product, VIAN aims to replace invasive injections for conditions like Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). Backed by strong preclinical data and ongoing clinical testing, VIAN is positioned to address significant unmet medical needs and disrupt the $15 billion retinal disease market.
Something looks off?